; "banner")
October 8, 2026
Alpha-9 Oncology Announces Presentation of Data for its GRPR-Targeting Imaging Compound 68Ga-A9-6217 at the European Association of Nuclear Medicine (EANM) 2026 Annual Congress
BOSTON, Mass. and VANCOUVER, British Columbia, October 8th, 2026 – Alpha-9...
September 8, 2026
Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors
Phase 1 study evaluates distinct 225Ac and 177Lu compounds in breast...
